Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study.

Front Oncol · 2021 · PMC8021904 · PMID 33833990

Europe PMC DOI

hedged sentence

0.1800

closest p · 3.6× alpha

0.1800

boldest claim

The sentences

showed a trendp = 0.18not close (p > 0.1)

Landmark analysis at 12 weeks also showed a trend toward better PFS in patients with mild irAEs, than in those with severe irAEs or without irAEs (HR 0.63, 95% CI: 0.32–1.25, p = 0.18).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.